AbbVie EVP Carlos Alban, for one, has argued in a letter seen by the Times that acceptance of Teva would dilute the association's "emphasis on innovation" and questioned how PhRMA would handle the "differences of opinion" and "internal conflicts" that could arise between Teva and the companies whose patents it seeks to invalidate. Teva, though, believes it belongs. While it may be the world's No. 1 generic producer, it also racked up more than $6 billion in branded sales last year, thanks in large part to multiple sclerosis blockbuster Copaxone.